All News

injection_1.jpg

Anakinra for Acute Crystal-Induced Arthritis

d Jack Cush, MD

A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.  

Read Article
FDA.panel_.jpg (keep)

Febuxostat Gets Reprieve from FDA Advisory Panel

d Jack Cush, MD

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol

Read Article
Giant-Cell_Vasculitis.jpg

IL-6 Blocker Succeeds in Real-World Vasculitis

d RheumNow

Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.

Read Article
doctors.%20fellows.jpg

Assessing the Performance of Aging Physicians

d Jack Cush, MD

A JAMA Viewpoint article examines the performance of aging surgeons and notes that the effects of aging affects physicians variably and that physician competency should be based on functional age (and abilities) rather than chronologic age. This argues against a mandatory retirement age for surgeons.

Read Article
renal.stone_.LBP_.jpg

Early Predictive Factors for Scleroderma Renal Crisis

d Jack Cush, MD

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for S

Read Article
diet.better.jpg

Diet and Weight Loss Improves Psoriatic Arthritis

d Jack Cush, MD

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

Read Article
Who thought this was possible? Numbers suggest this is rare. Tis wrong to use this to forge ahead with an unlikely PMR dx in the face of a normal CRP/ESR; but will you go so far as to order the expensive FDG-PET? https://t.co/RTkiUXO7lX

Links:

Dr. John Cush RheumNow ( View Tweet)

Vote now on this: https://t.co/j2Dfjdpuat

Links:

Dr. John Cush RheumNow ( View Tweet)

Today Jan 16th the FDA advisory comm will review the CV safety of anti-sclerostin drug Evenity (romosozumab). July 2018 the FDA issued a complete response letter for CV safety concerns. Amgen seeks indication for use in postmenopausal osteoporosis. https://t.co/IRr1nKJ43s

Links:

Dr. John Cush RheumNow ( View Tweet)

As always for travelers with fever and joint pain consider endemic viral and other infections, travel risk exposure including STDs and of course merely coincident diseases ( i.e. anchor heuristic) to make the right dx @medicalaxioms @RheumNow @CCalabreseDO https://t.co/ToMZkMI1vB

Links:

Leonard Calabrese LCalabreseDO ( View Tweet)

RA risk increased up to fivefold among patients with high CCP levels https://t.co/6VCMEsqx1p

Links:

Jeff Sparks jeffsparks ( View Tweet)

National registry of lupus nephritis pts w/ ESRD (n=20,974) between 1995-2014 showed that mortality declined from 11.1 to 6.7/100PY; Mortality declined for whites (HR 0.68), blacks (0.67) and Hispanics (0.51) and declined for CVD and infx by 44% & 63% https://t.co/0zDQmLymes

Links:

Dr. John Cush RheumNow ( View Tweet)

Combined study of Danbio (Denmark) and ARTIS (Sweden) RA registries showed that in 8987 treatment courses of abatacept, rituximab or tocilizumab there was no difference in Serious infection rates - ranging from 4.7-8.1 SIE/100 Pt Yrs. https://t.co/JpYDeSPdpy

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC report 5 Jan 2019: 7 million cases of influenza w/ an estimated 69,000 to 84,000 hospitalized for flu-related illness. H1N1 is the most common strain. Flu activity is widespread in 30 states https://t.co/kLsZjKDJen

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Year in Review : New Drugs, irAEs, Enbrel in court, Opioids, new JAKs, Hot PsA Trial, new Lupus drugs, Medical Marijuana, Expen$ive Rheum drugs, Senolytics. https://t.co/9VpM4yRGfY

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Video on RheumNow - an HLA-B27+ patient with Iritis, Enthesitis, Diarrhea. https://t.co/LusZttdAyw

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Video from RheumNow - The RA patients with Thrombocytopenia https://t.co/GHn6b6Z3kb

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up - discussing Gout FDA hearing, Gout Prevalence, ULT use, obesity, BMS-Celgene merger and more. Watch here https://t.co/J5xdqGYWAu Listen on iTunes or here> https://t.co/qHAO4E9cfX

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA AAC + DSRM advisory committee votes 19 yes, 2 no and 1 abstain on continued use of Uloric/febuxostat after reviewing CV risk in the CARES study. Await FDA decision, but Look for label changes.

Dr. John Cush RheumNow ( View Tweet)

QD Video - lessons from the Clinic - How to evaluate the Takayasu's arteritis patient. https://t.co/tZcOOKlcVU

Links:

Dr. John Cush RheumNow ( View Tweet)

×